ATG7 and neoplasm: Considering that CD8+ T cell-dependent metabolic remodeling, facilitated by ATG7 inhibition, improves the efficacy of anti-tumor immunity, we investigated whether targeting ATG7 could further improve anti-tumor efficacy of PD-1 blockade (Fig. 6A).